HRP960250A2 - Stable reagents for the preparation of radiopharmaceuticals - Google Patents

Stable reagents for the preparation of radiopharmaceuticals Download PDF

Info

Publication number
HRP960250A2
HRP960250A2 HR08/476,296A HRP960250A HRP960250A2 HR P960250 A2 HRP960250 A2 HR P960250A2 HR P960250 A HRP960250 A HR P960250A HR P960250 A2 HRP960250 A2 HR P960250A2
Authority
HR
Croatia
Prior art keywords
group
substituted
alkyl
independently selected
case
Prior art date
Application number
HR08/476,296A
Other languages
English (en)
Croatian (hr)
Inventor
Shuang Liu
Original Assignee
Shuang Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shuang Liu filed Critical Shuang Liu
Publication of HRP960250A2 publication Critical patent/HRP960250A2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008Peptides; Proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/75Fibrinogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR08/476,296A 1995-06-07 1996-06-04 Stable reagents for the preparation of radiopharmaceuticals HRP960250A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/476,296 US5750088A (en) 1993-03-30 1995-06-07 Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals

Publications (1)

Publication Number Publication Date
HRP960250A2 true HRP960250A2 (en) 1997-12-31

Family

ID=23891282

Family Applications (1)

Application Number Title Priority Date Filing Date
HR08/476,296A HRP960250A2 (en) 1995-06-07 1996-06-04 Stable reagents for the preparation of radiopharmaceuticals

Country Status (29)

Country Link
US (2) US5750088A (fr)
EP (1) EP0832068B1 (fr)
JP (1) JPH11507364A (fr)
KR (1) KR19990022573A (fr)
CN (1) CN1192733A (fr)
AR (1) AR003959A1 (fr)
AT (1) ATE233241T1 (fr)
AU (1) AU718683B2 (fr)
BR (1) BR9609003A (fr)
CA (1) CA2222183A1 (fr)
CZ (1) CZ380197A3 (fr)
DE (1) DE69626392T2 (fr)
EA (1) EA000742B1 (fr)
EE (1) EE9700313A (fr)
ES (1) ES2193245T3 (fr)
HR (1) HRP960250A2 (fr)
HU (1) HUP9901469A3 (fr)
IL (1) IL118468A0 (fr)
LT (1) LT4380B (fr)
LV (1) LV12044B (fr)
MX (1) MX9709126A (fr)
MY (1) MY133974A (fr)
NO (1) NO975678L (fr)
NZ (1) NZ310799A (fr)
PL (1) PL323995A1 (fr)
SI (1) SI9620076B (fr)
SK (1) SK163497A3 (fr)
WO (1) WO1996040637A1 (fr)
ZA (1) ZA964854B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69723242T2 (de) * 1996-03-13 2004-06-03 Bristol-Myers Squibb Pharma Co. Ternäre radiopharmazeutische komplexe
US6416733B1 (en) 1996-10-07 2002-07-09 Bristol-Myers Squibb Pharma Company Radiopharmaceuticals for imaging infection and inflammation
CN1239895A (zh) * 1996-10-07 1999-12-29 杜邦药品公司 用于对感染和炎症部位造影的放射药物
US20030124053A1 (en) * 1996-10-07 2003-07-03 Barrett John Andrew Radiopharmaceuticals for imaging infection and inflammation
US6403054B1 (en) * 1997-05-28 2002-06-11 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
AU3119199A (en) * 1998-04-03 1999-10-25 Du Pont Pharmaceuticals Company Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer
HRP990317A2 (en) * 1998-10-13 2000-06-30 Du Pont Pharm Co A process for the preparation of a thrombus imaging agent
US6794518B1 (en) * 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
EP1140864A2 (fr) * 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Medicaments antagonistes du recepteur de la vitronectine
CA2727746A1 (fr) 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company Medicaments antagonistes du recepteur de la vitronectine de quinolone
US6808698B1 (en) 1999-03-26 2004-10-26 Bristol-Myers Squibb Pharma Company Method for localization of blood clots
WO2000057787A2 (fr) * 1999-03-26 2000-10-05 Du Pont Pharmaceuticals Company Methode pour localiser des caillots de sang
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US20030220646A1 (en) * 2002-05-23 2003-11-27 Thelen Sarah L. Method and apparatus for reducing femoral fractures
US6534038B2 (en) 2000-04-07 2003-03-18 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
EP1347784A2 (fr) * 2000-11-03 2003-10-01 Bristol-Myers Squibb Pharma Company Double imagerie isotopique simultanee d'une perfusion et d'une inflammation cardiaque
GB0031592D0 (en) * 2000-12-28 2001-02-07 Nycomed Amersham Plc Stabilised radiopharmaceutical compositions
US6838074B2 (en) 2001-08-08 2005-01-04 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
HUP0401904A3 (en) * 2001-08-08 2009-01-28 Bristol Myers Squibb Pharma Co Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7319149B2 (en) * 2003-06-13 2008-01-15 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7317104B2 (en) 2003-06-13 2008-01-08 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
CN100418585C (zh) * 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
WO2007005491A1 (fr) * 2005-06-30 2007-01-11 Bristol-Myers Squibb Pharma Company Conjugues d'hydrazide en tant qu'agents d'imagerie
WO2007046411A1 (fr) * 2005-10-19 2007-04-26 Dainippon Sumitomo Pharma Co., Ltd. Procede de stabilisation d'un compose d'isoxazole
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
CN104592128A (zh) * 2005-12-20 2015-05-06 阿斯利康(瑞典)有限公司 作为gabaa受体调节剂的取代的噌啉衍生物及其合成方法
CA2673683C (fr) 2007-01-11 2014-07-29 Critical Outcome Technologies, Inc. Composes et methode de traitement un cancer
TW200911760A (en) * 2007-06-19 2009-03-16 Astrazeneca Ab Compounds and uses thereof
CA2710039C (fr) * 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarnazones et composes associes, et methodes de traitement du cancer
EP3023426A1 (fr) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Composés inhibiteurs à base de thiosemicarbazone et procédés de traitement du cancer
FR2940652B1 (fr) * 2008-12-29 2011-02-11 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
ES2511917T3 (es) 2008-12-29 2014-10-23 Sanofi Derivados de 2-piridin-2-il-pirazol-3(2H)-ona, su preparación y su aplicación en terapéutica
EP2382205B1 (fr) 2008-12-29 2014-04-23 Sanofi Dérivés de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur préparation et leur application en thérapeutique comme activateurs de hif
FR2949468B1 (fr) * 2009-08-28 2011-09-30 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
EP2552915B1 (fr) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Composés pour le traitement du vih
FR2967671A1 (fr) * 2010-11-24 2012-05-25 Pf Medicament Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
CN110818624B (zh) * 2019-11-22 2022-11-22 华东理工大学 吡啶季铵盐腙类化合物及制备方法与在抗菌或香料缓释中的应用
CN112999369B (zh) * 2021-03-03 2022-02-25 江苏元本生物科技有限公司 一种her2亲合体放射性核素标记物组合物及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
CA1300608C (fr) * 1985-05-10 1992-05-12 Edward A. Deutsch Agents de visualisation du myocarde 99 mtc (iii) ayant un potentiel redox pratiquement negatif in vivo
GB8624272D0 (en) * 1986-10-09 1986-11-12 Amersham Int Plc Cationic complexes of tc-99m
US5217705A (en) 1987-09-25 1993-06-08 Neorx Corporation Method of diagnosing blood clots using fibrin-binding proteins
AU639409B2 (en) 1987-12-10 1993-07-29 La Jolla Cancer Research Foundation Conformationally stabilized cell adhesion peptides
JPH07110869B2 (ja) * 1988-03-09 1995-11-29 セ・イ・エス・ビオ・アンテルナシヨナル 放射性医薬品として使用できる99mTc、186Reまたは188Reの窒化物錯体の製造方法
GB8808414D0 (en) * 1988-04-11 1988-05-11 Amersham Int Plc Ligands & cationic complexes thereof with technetium-99m
EP0412115A4 (en) 1988-04-29 1991-11-13 New England Deaconess Hospital Corporation Hybrid peptides and methods of their use
US5002754A (en) * 1988-06-15 1991-03-26 University Of Cincinnati Technetium (III/II) imaging agents
HUT55799A (en) 1988-09-29 1991-06-28 Biogen Inc Process for producing hirudine-like peptides
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5270030A (en) 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
GB8902362D0 (en) * 1989-02-03 1989-03-22 Amersham Int Plc Cationic complexes of technetium-99m
IL93432A (en) * 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions
US5206370A (en) * 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
US4917879A (en) * 1989-05-19 1990-04-17 University Of Cincinnati 99MTC(III) myocardial imaging agents that are effective in humans
US4957728A (en) * 1989-05-19 1990-09-18 University Of Cincinnati Kit for preparing Tc (III)-99m myocardial imaging agents that are effective in humans
GB8914020D0 (en) 1989-06-19 1989-08-09 Antisoma Ltd Synthetic peptides for use in thrombus detection
EP0410537A1 (fr) 1989-07-28 1991-01-30 Merck & Co. Inc. Antagonistes pour le récepteur du fibrinogène
GB8919488D0 (en) * 1989-08-29 1989-10-11 Amersham Int Plc New cores for technetium radiopharmaceuticals
ZA907743B (en) 1989-10-03 1991-07-31 Merrell Dow Pharma Radiolabeled anticoagulant peptides
US5086069A (en) 1990-02-05 1992-02-04 Rorer Pharmaceutical Corporation Anti-thrombotic peptide and pseudopeptide derivatives
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
FR2664166A1 (fr) * 1990-07-04 1992-01-10 Cis Bio Int Procede de preparation de complexes nitruro de metaux de transition utilisables comme produits radiopharmaceutiques ou pour la synthese de nouveaux produits radiopharmaceutiques.
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
DE69126124T2 (de) * 1990-09-28 1997-08-28 Neorx Corp Polymere träger zur freisetzung kovalent gebundener wirkstoffe
US5112594A (en) * 1991-04-04 1992-05-12 Mallinckrodt Medical, Inc. Kit for preparing a technetium-99m myocardial imaging agent
JP2774378B2 (ja) 1991-02-08 1998-07-09 ダイアテク,インコーポレイテッド 映像用テクネチウム−99m標識化ポリペプチド
FR2679452B1 (fr) * 1991-07-22 1993-11-12 Cis Bio International Produit radiopharmaceutique ayant notamment un tropisme cerebral, comportant un complexe nitruro d'un metal de transition, et son procede de preparation.
US5362852A (en) * 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
DK0641222T3 (da) 1992-05-21 2000-12-11 Diatide Inc Peptider mærket med technetium-99m til trombeafbildning
GB2268494B (en) 1992-07-08 1996-08-21 Kenneth Francis Prendergast Imaging compositions
FR2698272B1 (fr) * 1992-11-20 1994-12-30 Cis Bio Int Procédé de marquage cellulaire au moyen de complexes nitruro-bis (dithiocarbamato)Tc-99m et trousse pour la mise en Óoeuvre de ce procédé.
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders

Also Published As

Publication number Publication date
PL323995A1 (en) 1998-04-27
EA199800025A1 (ru) 1998-06-25
HUP9901469A2 (hu) 1999-08-30
MY133974A (en) 2007-11-30
DE69626392D1 (de) 2003-04-03
WO1996040637A1 (fr) 1996-12-19
HUP9901469A3 (en) 2000-02-28
AR003959A1 (es) 1998-09-30
EP0832068B1 (fr) 2003-02-26
KR19990022573A (ko) 1999-03-25
NO975678L (no) 1998-02-06
MX9709126A (es) 1998-03-31
BR9609003A (pt) 1999-12-14
SI9620076A (sl) 1998-08-31
SK163497A3 (en) 1998-10-07
JPH11507364A (ja) 1999-06-29
LV12044B (en) 1998-09-20
NZ310799A (en) 2000-01-28
AU718683B2 (en) 2000-04-20
EA000742B1 (ru) 2000-02-28
ES2193245T3 (es) 2003-11-01
CZ380197A3 (cs) 1998-07-15
EP0832068A1 (fr) 1998-04-01
NO975678D0 (no) 1997-12-05
LT97191A (en) 1998-04-27
DE69626392T2 (de) 2004-04-22
IL118468A0 (en) 1996-09-12
LT4380B (lt) 1998-09-25
US5750088A (en) 1998-05-12
EE9700313A (et) 1998-06-15
LV12044A (lv) 1998-05-20
ATE233241T1 (de) 2003-03-15
CA2222183A1 (fr) 1996-12-19
AU6166196A (en) 1996-12-30
SI9620076B (sl) 2000-02-29
CN1192733A (zh) 1998-09-09
ZA964854B (en) 1997-12-08
US6015904A (en) 2000-01-18

Similar Documents

Publication Publication Date Title
HRP960250A2 (en) Stable reagents for the preparation of radiopharmaceuticals
US5744120A (en) Ternary radiopharmaceutical complexes
EP0692982B1 (fr) ANTAGONISTES RADIOMARQUES DES RECEPTEURS PLAQUETTAIRES GPIIb/IIIa, UTILISES COMME AGENTS DE VISUALISATION POUR LE DIAGNOSTIC DES AFFECTIONS THROMBOEMBOLIQUES
CZ20032597A3 (cs) Analogy kyseliny askorbové pro metaloradiofarmaceutika
US5879659A (en) Ternary radiopharmaceutical complexes
US6524554B1 (en) Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer
EP0888130B1 (fr) Complexes ternaires radio-pharmaceutiques
JP2023549469A (ja) 新規cxcr4標的化合物
US20050010038A1 (en) Chelants and macrocyclic metal complex radiopharmaceuticals thereof
HRP970139A2 (en) New ternary radiopharmaceutical complexes

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODBC Application rejected